Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

RFL
Rafael Holdings, Inc. Class B Common Stock
stock NYSE

At Close
Mar 2, 2026 3:59:30 PM EST
1.47USD+15.748%(+0.20)455,914
1.46Bid   1.52Ask   0.06Spread
Pre-market
Mar 2, 2026 8:50:30 AM EST
1.33USD+4.724%(+0.06)1,157
After-hours
0.00USD0.000%(0.00)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 21, 2022
07:05AM EST  Rafael Holdings Reports Bill Conkling Will Assume Role Of CEO From Ameet Mallik, Effective Feb. 1, 2022   Benzinga
07:00AM EST  William Bill Conkling to   GlobeNewswire Inc
Jan 18, 2022
08:34AM EST  Rafael Pharmaceuticals Announces Ongoing Successful Enrollment And Opening Of Additional Sites For Phase 2 Clinical Trial Of CPI-613 (Devimistat) In Combination With Gemcitabine And Cisplatin In Patients With Biliary Tract Cancer   Benzinga
08:30AM EST  Rafael Pharmaceuticals Announces Ongoing Successful Enrollment and   GlobeNewswire Inc
Jan 6, 2022
08:34AM EST  Rafael Pharmaceuticals Announces Completion Of Dose Escalation With No Dose-Limiting Toxicity In First Cohort Of APOLLO 613 Phase 1/2 Clinical Trial Of CPI-613 In Patients With Relapsed Clear Cell Sarcoma   Benzinga
08:30AM EST  Rafael Pharmaceuticals Announces Successful Completion of Dose   GlobeNewswire Inc
Dec 15, 2021
04:30PM EST  Rafael Holdings Reports First Quarter Fiscal 2022 Financial and   GlobeNewswire Inc
Dec 13, 2021
08:14AM EST  Rafael Pharmaceuticals Announces Published Data On CPI-613 From Phase 2 Clinical Trial For Refractory Burkitt Lymphoma At The 2021 American Society Of Hematology Annual Meeting and Exposition   Benzinga
08:00AM EST  Rafael Pharmaceuticals Announces Published Data on   GlobeNewswire Inc
Dec 10, 2021
01:30PM EST  Rafael Shares Drop 12%   RTTNews
Nov 22, 2021
07:27AM EST  Rafael Holdings Announces Ameet Mallik Will Resign From CEO And Remain As A Director; Co. Elects Howard Jonas As Chairman Of The Board   Benzinga
07:07AM EST  Rafael Holdings Chair of Board to Take Over CEO Responsibilities   Benzinga
07:00AM EST  - Ameet Mallik to Transition CEO Role to Chairman, Howard Jonas, and Will Remain a Highly Engaged Member of the Companys Board of Directors and Chair Newly Established Transition Committee -   GlobeNewswire Inc
Nov 11, 2021
09:02AM EST  Rafael Pharmaceuticals Announces First Patient Enrolled In APOLLO 613 Phase 1/2 Clinical Trial Of CPI-613 (Devimistat) In Patients With Relapsed Clear Cell Sarcoma   Benzinga
09:00AM EST  Rafael Pharmaceuticals Announces First Patient Enrolled in APOLLO   GlobeNewswire Inc
Nov 3, 2021
09:22AM EDT  Rafael Holdings Says European Medicines Agency Grants Orphan Drug Designation To Co's CPI-613 For Treatment Of Patients With Relapsed Or Refractory Burkitt's Lymphoma   Benzinga
09:00AM EDT  Rafael Pharmaceuticals, Inc. (Rafael or the Company), a company focused on the growing field of cancer metabolism-based therapeutics, today announced that the European Medicines Agency (EMA) has granted orphan drug designation to CPI-613 (devimistat) for the treatment of Burkitts lymphoma.   GlobeNewswire Inc
Oct 29, 2021
06:14AM EDT  The following are some of the stocks making big moves in Friday's pre-market trading (as of 05.45 A.M. EDT).   RTTNews
Oct 28, 2021
02:45PM EDT  Mid-Afternoon Market Update: Dow Surges 160 Points; Wolfspeed Shares Gain After Q1 Results   Benzinga
12:16PM EDT  Mid-Day Market Update: Nasdaq Rises Over 1%; Rafael Holdings Shares Slide   Benzinga
10:44AM EDT  Mid-Morning Market Update: Markets Rise; Caterpillar Profit Beats Expectations   Benzinga
08:00AM EDT  Rafael Pharmaceuticals Provides Update on Pivotal Phase 3 Clinical   GlobeNewswire Inc
07:16AM EDT  UPDATE: Rafael Holdings Announces Phase 3 Clinical Trial In Metastatic Pancreatic Cancer Did Not Meet Its Primary Endpoint of Improved Overall Survival; Co. Also Announced The IDMC Recommended The Phase 3 Clinical Trial In Relapsed Or Refractory Acute Myeloid Leukemia Be Stopped Due To Lack Of Efficacy   Benzinga
07:15AM EDT  UPDATE: Rafael Holdings Announces Phase 3 Clinical Trial In Metastatic Pancreatic Cancer Did Not Meet Its Primary Endpoint of Improved Overall Survival; Co. Also Announced The IDMC Recommended The Phase 3 Clinical Trial In Relapsed   Benzinga
07:13AM EDT  Rafael Holdings Provides Update On Rafael Pharmaceuticals' Two Phase 3 Trials Of CPI-613, AVENGER 500 In Metastatic Pancreatic Cancer And ARMADA 2000 In Relapsed Or Refractory Acute Myeloid Leukemia   Benzinga
07:00AM EDT  Phase 3 Clinical Trial in Metastatic Pancreatic Cancer Did Not Meet its Primary Endpoint of Improved Overall Survival   GlobeNewswire Inc
Oct 18, 2021
05:30PM EDT  Rafael Holdings, Inc., (NYSE: RFL), announced that today it made a grant to Dr. Mary Margaret Huizingaof options to purchase 122,341 shares of Class B common stock of the Company with an exercise price equal to $30.54, the closing price of the Class B common stock on October 15, 2021, the trading day prior to the grant.   GlobeNewswire Inc
04:32PM EDT  Rafael Holdings Q4 EPS $(0.75) Down From $(0.34) YoY, Sales $1.00M Down From $1.20M YoY   Benzinga
04:30PM EDT  We expect Rafael Pharmaceuticals to report top line data from its AVENGER 500 Phase 3 registrational clinical trial in metastatic pancreatic cancer this calendar year   GlobeNewswire Inc
Oct 6, 2021
11:16AM EDT  Rafael Up 8%, Appoints Mimi Huizinga As New CDMO   RTTNews
10:23AM EDT  Mid-Morning Market Update: Markets Open Lower; Acuity Brands Posts Upbeat Q4 Results   Benzinga
06:36AM EDT  Rafael Holdings Appoints Mimi Huizinga As Chief Development And Medical Officer, Effective October 18   RTTNews
06:31AM EDT  Rafael Holdings Appoints Mimi Huizinga, MD, MPH as Chief Development and   PR Newswire
Sep 27, 2021
08:15AM EDT  Rafael Pharma Reports APOLLO613 Phase 1/2 Trial Of CPI-613 In Combo With Hydroychloroquine In Patients With Relapse Clear Cell Sarcoma Begins Enrolling In Duarte, California   Benzinga
08:00AM EDT  Rafael Pharmaceuticals Announces APOLLO613 Phase I/II Clinical   GlobeNewswire Inc
Sep 24, 2021
04:30PM EDT  Experienced Global Biopharmaceutical Executive to Build a Fully Integrated Cancer Metabolism Therapeutics Company and Announces Inducement Grant Under NYSE Rule 303A.08   PR Newswire
Sep 17, 2021
04:01PM EDT  Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08   PR Newswire
Sep 14, 2021
08:36AM EDT  Rafael Holdings Names Patrick Fabbio CFO   RTTNews
08:27AM EDT  Rafael Holdings Appoints Patrick Fabbio as Chief Financial Officer   PR Newswire
Aug 28, 2021
01:06PM EDT  The Past Week's Notable Insider Buys: Callon Petroleum, Cricut, Krispy Kreme And More   Benzinga
Aug 26, 2021
02:48PM EDT  Mid-Afternoon Market Update: Pure Storage Rises Following Strong Q2 Results; SelectQuote Shares Plunge   Benzinga
12:13PM EDT  Mid-Day Market Update: Dow Tumbles Over 100 Points; Ascendis Pharma Shares Spike Higher   Benzinga
08:00AM EDT  Rafael Pharmaceuticals, Inc. (Rafael or the Company), a leader in the growing field of cancer metabolism-based therapeutics, announced that Sanjeev Luther, President and CEO, will present at the World Orphan Drug Congress taking place on August 25-27 at the Gaylord National Resort & Convention Center in Oxon Hill, Maryland.   GlobeNewswire Inc
Aug 25, 2021
12:28PM EDT  Rafael Holdings CEO Jonas Howard Buys 112,561 Shares At Average Price Of $44.92   Benzinga
10:01AM EDT  Rafael Pharma Reports Successful Completion Of Phase 1b Trial, Begins Phase 2 Trial For CPI-613 In Combo With Gemcitabine, Cisplatin In Patients With Biliary Tract Cancer   Benzinga
10:01AM EDT  Rafael Pharmaceuticals Announces the Successful Completion of   GlobeNewswire Inc
Aug 24, 2021
04:02PM EDT  Rafael Holdings Announces Closing of $104.2 Million Private Placement   PR Newswire
Aug 20, 2021
07:07AM EDT  Rafael Holdings Agreements To Sell $104.2 Mln Securities In A Private Placement   RTTNews
07:01AM EDT  Rafael Holdings Announces $104.2 Million Private Placement   PR Newswire
Aug 17, 2021
10:20AM EDT  Rafael Holdings Announces Appointment Of Three Senior Biopharmaceutical Leaders To Executive Management Team   RTTNews
10:12AM EDT  Biopharmaceutical Executives to Build a Fully Integrated Cancer Metabolism Therapeutics Company   PR Newswire
Jul 1, 2021
08:08AM EDT  Rafael Pharmaceuticals Announces Preplanned Interim Futility Analysis Of Pivotal Phase 3 Trial Of CPI-613 For Relapsed Or Refractory Acute Myeloid Leukemia; Says Independent Data Monitoring Committee Recommended Co. Continue Trial As Is   Benzinga
08:00AM EDT  Rafael Pharmaceuticals Announces Positive Preplanned Interim   GlobeNewswire Inc
Jun 30, 2021
08:00AM EDT  Rafael Pharmaceuticals, Inc. (Rafael or the Company), a leader in the growing field of cancer metabolism-based therapeutics, today announced that data on its lead compound, devimistat, has been selected for an oral presentation at the 2021 European Society of Medical Oncology World Gastrointestinal Congress (ESMO), taking place June 30 through July 3, 2021.   GlobeNewswire Inc
Jun 29, 2021
11:02AM EDT  Rafael Holdings Says FDA Grants Rafael Pharmaceuticals Orphan Drug Designation For CPI-613 For Treatment Of Biliary Cancer   Benzinga
11:00AM EDT  Rafael Pharmaceuticals, Inc. (Rafael or the Company), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for CPI-613 (devimistat) for the treatment of biliary cancer.   GlobeNewswire Inc
Jun 24, 2021
12:18PM EDT  RAFAEL HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Rafael Holdings, Inc. - RFL   Business Wire
Jun 23, 2021
12:40PM EDT  Rafael Holdings and Rafael Pharmaceuticals Management Presented at the Raymond   PR Newswire
Jun 21, 2021
06:34AM EDT  Rafael Holdings Enters Merger Agreement With Rafael Pharma   RTTNews
06:30AM EDT  Rafael Holdings Announces Strategic Merger with Rafael Pharmaceuticals to Form   PR Newswire
Jun 14, 2021
04:46PM EDT  Rafael Holdings Q3 EPS $(0.15) Down From $(0.14) YoY, Sales $1.00M Down From $1.22M YoY   Benzinga
04:45PM EDT  Rafael Holdings Reports Third Quarter Fiscal Year 2021 Results   PR Newswire
04:45PM EDT  Rafael Holdings Appoints Three Highly Experienced Biopharmaceutical Leaders to   PR Newswire
May 28, 2021
04:31PM EDT  Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08   PR Newswire
02:41PM EDT  Mid-Afternoon Market Update: Dow Rises Over 100 Points; Mannatech Shares Spike Higher   Benzinga
May 26, 2021
09:09AM EDT  Rafael Pharma Highlights Presentation Of Data On Pancreatic Cancer, Biliary Tract Cancer Candidate At American Society Of Clinical Oncology Jun. 4   Benzinga
09:00AM EDT  Rafael Pharmaceuticals to Present New Pancreatic Cancer and   GlobeNewswire Inc
Apr 16, 2021
05:00PM EDT  Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08   PR Newswire
Mar 30, 2021
09:03AM EDT  Rafael Pharmaceuticals Crosses Enrollment Of 150 Patients In Pivotal Phase 3 Trial Of CPI-613 For Relapsed Or Refractory Acute Myeloid Leukemia   Benzinga
09:00AM EDT  Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in   GlobeNewswire Inc
Mar 17, 2021
04:32PM EDT  Rafael Holdings Q2 EPS $(0.50) Down From $(0.08) YoY, Sales $1.00M Down From $1.24M YoY   Benzinga
04:30PM EDT  Rafael Holdings Reports Second Quarter Fiscal Year 2021 Results   PR Newswire
Mar 11, 2021
05:05PM EST  Rafael Holdings Names Ameet Mallik CEO, Succeeding Founder, Howard Jonas   Benzinga
05:00PM EST  Rafael Holdings Enhances Senior Management Team with Additions of Ameet Mallik,   PR Newswire
Feb 11, 2021
11:21AM EST  Stocks That Hit 52-Week Highs On Thursday   Benzinga
Feb 10, 2021
09:00AM EST  LipoMedix Announces Manufacturing Agreement with ForDoz for   GlobeNewswire Inc
Jan 20, 2021
04:38PM EST  Rafael Holdings Inc Files For Offering Of Class B Common Stock Of Up To $6.95M   Benzinga
Jan 19, 2021
11:30AM EST  Rafael Pharmaceuticals, Inc. (Rafael or the Company), a leader in the growing field of cancer metabolism-based therapeutics, today announced that Sanjeev Luther, President and CEO, and Timothy S. Pardee, M.D., Ph.D., Co-Chief Medical Officer of the Company, will present at the B. Riley Securities Virtual Oncology Investor Conference on Wednesday, Jan. 20.   GlobeNewswire Inc
Jan 13, 2021
09:00AM EST  Rafael Pharmaceuticals, Inc. (Rafael or the Company), a leader in the growing field of cancer metabolism-based therapeutics, today announced that Sanjeev Luther, President and Chief Executive Officer, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference, on Thursday, Jan. 14.   GlobeNewswire Inc
Dec 22, 2020
08:38AM EST  Barer Institute Reports Licensing Deal With Princeton University's Office Of Techy Licensing For SHMT Inhibitor Program   RTTNews
08:31AM EST  Barer Institute Announces Licensing Agreement with Princeton University's   PR Newswire
Dec 15, 2020
04:31PM EST  Rafael Holdings Q1 EPS $(0.09) Up From $(0.10) YoY, Sales $1.10M Down From $1.21M YoY   Benzinga
04:31PM EST  Rafael Holdings Reports First Quarter Fiscal Year 2021 Results   PR Newswire
11:09AM EST  Rafael Pharmaceuticals, Inc. (Rafael or the Company), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Companys lead compound, CPI-613 (devimistat), for the treatment of acute myeloid leukemia (AML).   GlobeNewswire Inc
09:01AM EST  Rafael Pharmaceuticals Receives FDA Fast Track Designation For CPI-613 For the Treatment Of Acute Myeloid Leukemia   Benzinga
09:00AM EST  Rafael Pharmaceuticals, Inc. (Rafael or the Company), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Companys lead compound, CPI-613 (devimistat), for the treatment of acute myeloid leukemia (AML).   GlobeNewswire Inc
Dec 1, 2020
12:05PM EST  Rafael Pharmaceuticals Partners with Saras Cure   GlobeNewswire Inc
09:06AM EST  Rafael Pharma Reports Partnership With Sara's Cure, SARC For Launch Of Phase 2 Trial For CPI-613 In Combo With Hydroxychloroquine for Patients With Clear Cell Sarcoma Of Soft   Benzinga
09:00AM EST  Rafael Pharmaceuticals Partners with Saras Cure   GlobeNewswire Inc
Nov 10, 2020
09:14AM EST  Rafael Pharma Reports Receives FDA Fast Track Designation For CPI-613 For Treatment Of Pancreatic Cancer   Benzinga
09:00AM EST  Rafael Pharmaceuticals, Inc. (Rafael or the Company), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Companys lead compound, CPI-613 (devimistat), for the treatment of metastatic pancreatic cancer.   GlobeNewswire Inc
Oct 29, 2020
05:11PM EDT  Rafael Holdings Q4 EPS $(0.34) Down From $(0.16) YoY, Sales $1.20M Down From $1.40M YoY   Benzinga
04:31PM EDT  Rafael Holdings Reports Fourth Quarter and Full Fiscal Year 2020 Results   PR Newswire
09:31AM EDT  FDA Grants Rafael Pharmaceuticals Orphan Drug Designation For CPI-613 For Treatment Of Soft Tissue Sarcoma   Benzinga
Oct 27, 2020
09:07AM EDT  Rafael Pharmaceuticals Crosses Enrollment Of 100th Patient In Phase 3 Trial (ARMADA 2000) Of CPI-613 (Devimistat) For Relapsed Or Refractory Acute Myeloid Leukemia (AML)   Benzinga
09:00AM EDT  Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in   GlobeNewswire Inc
Oct 20, 2020
09:08AM EDT  Rafael Holdings Reports New Phase 1 Study Begins To Evaluate Co's Lead Compound CPI-613 For Patients With Pancreatic Cancer In Japan   Benzinga
09:00AM EDT  A New Phase 1 Study Began to Evaluate Rafael   GlobeNewswire Inc
Aug 24, 2020
08:31AM EDT  Rafael Holdings to Present at LD Micro Investor Conference   PR Newswire
Aug 6, 2020
10:11AM EDT  Rafael Pharmaceuticals Earlier Announced Achieved Target Enrollment Of 500 Patients In Pivotal Phase 3 Trial (AVENGER 500) Of CPI-613 For Patients With Metastatic Pancreatic Cancer   Benzinga
10:11AM EDT  Rafael Pharmaceuticals Achieves Target Enrollment Of 500 Patients In Pivotal Phase 3 Trial (AVENGER 500) Of CPI-613 For Patients With Metastatic Pancreatic Cancer   Benzinga
Jul 21, 2020
09:00AM EDT  Rafael Pharmaceuticals Crosses Midpoint of Enrollment to First   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC